 Thomas Bak
Concepts (133)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 22 | 2022 | 841 | 0.900 |
Why?
| | Robotic Surgical Procedures | 4 | 2026 | 207 | 0.770 |
Why?
| | Kidney Transplantation | 4 | 2026 | 732 | 0.600 |
Why?
| | Living Donors | 8 | 2022 | 289 | 0.330 |
Why?
| | Tissue Donors | 2 | 2026 | 427 | 0.280 |
Why?
| | Hepatic Artery | 3 | 2004 | 55 | 0.280 |
Why?
| | Brain Death | 1 | 2026 | 60 | 0.230 |
Why?
| | Tissue and Organ Procurement | 4 | 2026 | 350 | 0.230 |
Why?
| | Polycystic Kidney Diseases | 1 | 2026 | 82 | 0.230 |
Why?
| | Nephrectomy | 1 | 2026 | 172 | 0.220 |
Why?
| | Duodenal Diseases | 1 | 2004 | 8 | 0.220 |
Why?
| | Intestinal Fistula | 1 | 2004 | 18 | 0.210 |
Why?
| | Carcinoma, Hepatocellular | 5 | 2007 | 379 | 0.210 |
Why?
| | Vascular Fistula | 1 | 2004 | 22 | 0.210 |
Why?
| | Aneurysm, False | 1 | 2004 | 46 | 0.210 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 1 | 2026 | 244 | 0.190 |
Why?
| | Immunosuppressive Agents | 8 | 2008 | 840 | 0.190 |
Why?
| | Liver Neoplasms | 5 | 2007 | 787 | 0.180 |
Why?
| | Graft Survival | 7 | 2026 | 534 | 0.170 |
Why?
| | Body Mass Index | 2 | 2026 | 2470 | 0.160 |
Why?
| | Cholangitis, Sclerosing | 4 | 2008 | 61 | 0.160 |
Why?
| | Delayed Graft Function | 2 | 2026 | 54 | 0.120 |
Why?
| | Operative Time | 2 | 2026 | 195 | 0.110 |
Why?
| | Sirolimus | 3 | 2007 | 283 | 0.110 |
Why?
| | Liver Failure | 2 | 2008 | 83 | 0.110 |
Why?
| | Donor Selection | 1 | 2016 | 79 | 0.110 |
Why?
| | Airway Extubation | 1 | 2016 | 60 | 0.110 |
Why?
| | Postoperative Complications | 3 | 2026 | 3022 | 0.110 |
Why?
| | Treatment Outcome | 10 | 2026 | 11947 | 0.100 |
Why?
| | Retrospective Studies | 12 | 2026 | 17560 | 0.100 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2016 | 190 | 0.100 |
Why?
| | Cholestasis | 1 | 2016 | 217 | 0.100 |
Why?
| | Obesity | 2 | 2026 | 3149 | 0.100 |
Why?
| | Middle Aged | 19 | 2026 | 36821 | 0.100 |
Why?
| | Graft Rejection | 3 | 2007 | 523 | 0.090 |
Why?
| | Adult | 15 | 2026 | 41405 | 0.080 |
Why?
| | Tacrolimus | 3 | 2007 | 196 | 0.080 |
Why?
| | Female | 20 | 2026 | 80076 | 0.070 |
Why?
| | Hepatitis, Autoimmune | 1 | 2008 | 16 | 0.070 |
Why?
| | Hypoxia | 1 | 2016 | 1208 | 0.070 |
Why?
| | Male | 20 | 2026 | 73950 | 0.070 |
Why?
| | Hepatic Veins | 1 | 2008 | 34 | 0.070 |
Why?
| | Cadaver | 3 | 2004 | 316 | 0.070 |
Why?
| | Humans | 27 | 2026 | 147293 | 0.060 |
Why?
| | Chemoembolization, Therapeutic | 2 | 2007 | 89 | 0.060 |
Why?
| | Warm Ischemia | 1 | 2026 | 28 | 0.060 |
Why?
| | Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2006 | 38 | 0.060 |
Why?
| | Disease Transmission, Infectious | 1 | 2006 | 69 | 0.060 |
Why?
| | Bile Ducts | 2 | 2022 | 68 | 0.060 |
Why?
| | Anastomosis, Roux-en-Y | 2 | 2022 | 26 | 0.060 |
Why?
| | Hepatectomy | 1 | 2008 | 280 | 0.060 |
Why?
| | Herpes Simplex | 1 | 2006 | 102 | 0.060 |
Why?
| | Portal Vein | 1 | 2006 | 124 | 0.060 |
Why?
| | Adrenal Cortex Hormones | 1 | 2008 | 487 | 0.050 |
Why?
| | Venous Thrombosis | 1 | 2006 | 199 | 0.050 |
Why?
| | Vena Cava, Inferior | 1 | 2004 | 83 | 0.050 |
Why?
| | Survival Analysis | 4 | 2008 | 1386 | 0.050 |
Why?
| | Choledochostomy | 1 | 2022 | 10 | 0.050 |
Why?
| | Reoperation | 3 | 2016 | 644 | 0.050 |
Why?
| | Hepatocytes | 1 | 2003 | 224 | 0.050 |
Why?
| | Hospital Costs | 1 | 2003 | 130 | 0.040 |
Why?
| | Aged | 5 | 2026 | 26514 | 0.040 |
Why?
| | Hepatitis C | 1 | 2003 | 256 | 0.040 |
Why?
| | Pancreas Transplantation | 1 | 2000 | 71 | 0.040 |
Why?
| | Vascular Surgical Procedures | 1 | 2004 | 347 | 0.040 |
Why?
| | Length of Stay | 1 | 2026 | 1371 | 0.040 |
Why?
| | Recurrence | 3 | 2008 | 1151 | 0.040 |
Why?
| | Glucocorticoids | 1 | 2003 | 537 | 0.040 |
Why?
| | Kidney | 1 | 2026 | 1511 | 0.030 |
Why?
| | Disease-Free Survival | 2 | 2008 | 779 | 0.030 |
Why?
| | Time Factors | 3 | 2016 | 7173 | 0.030 |
Why?
| | Shock | 1 | 2016 | 110 | 0.030 |
Why?
| | Risk Factors | 4 | 2016 | 11017 | 0.030 |
Why?
| | Erythrocyte Transfusion | 1 | 2016 | 225 | 0.020 |
Why?
| | Health Care Rationing | 2 | 2004 | 56 | 0.020 |
Why?
| | Cause of Death | 1 | 2016 | 475 | 0.020 |
Why?
| | Hemoglobins | 1 | 2016 | 386 | 0.020 |
Why?
| | Follow-Up Studies | 3 | 2008 | 5476 | 0.020 |
Why?
| | Cyclosporine | 2 | 2003 | 257 | 0.020 |
Why?
| | Neoplasm Staging | 2 | 2007 | 1492 | 0.020 |
Why?
| | Cohort Studies | 3 | 2008 | 6099 | 0.020 |
Why?
| | Patient Selection | 2 | 2004 | 746 | 0.020 |
Why?
| | Liver | 2 | 2007 | 1916 | 0.020 |
Why?
| | Tissue and Organ Harvesting | 1 | 2008 | 78 | 0.020 |
Why?
| | Functional Laterality | 1 | 2008 | 241 | 0.020 |
Why?
| | Portography | 1 | 2006 | 7 | 0.020 |
Why?
| | Adolescent | 3 | 2016 | 22825 | 0.020 |
Why?
| | Ultrasonics | 1 | 2006 | 50 | 0.020 |
Why?
| | Delayed-Action Preparations | 1 | 2007 | 191 | 0.010 |
Why?
| | Simplexvirus | 1 | 2006 | 82 | 0.010 |
Why?
| | Blood Vessels | 1 | 2007 | 167 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 2 | 2006 | 2791 | 0.010 |
Why?
| | Neoplasm Invasiveness | 1 | 2007 | 512 | 0.010 |
Why?
| | Treatment Failure | 1 | 2006 | 360 | 0.010 |
Why?
| | Colorado | 2 | 2008 | 4591 | 0.010 |
Why?
| | Kaplan-Meier Estimate | 1 | 2008 | 975 | 0.010 |
Why?
| | Safety | 1 | 2007 | 358 | 0.010 |
Why?
| | Elective Surgical Procedures | 1 | 2006 | 203 | 0.010 |
Why?
| | Preoperative Care | 1 | 2007 | 381 | 0.010 |
Why?
| | Biomarkers | 1 | 2016 | 4351 | 0.010 |
Why?
| | Waiting Lists | 1 | 2006 | 268 | 0.010 |
Why?
| | Survival | 1 | 2004 | 38 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2008 | 1344 | 0.010 |
Why?
| | Transplants | 1 | 2004 | 38 | 0.010 |
Why?
| | alpha-Fetoproteins | 1 | 2004 | 42 | 0.010 |
Why?
| | Microsomes, Liver | 1 | 2003 | 85 | 0.010 |
Why?
| | Muromonab-CD3 | 1 | 2003 | 6 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2000 | 3952 | 0.010 |
Why?
| | Cost Control | 1 | 2003 | 38 | 0.010 |
Why?
| | Alkaline Phosphatase | 1 | 2003 | 145 | 0.010 |
Why?
| | Outpatients | 1 | 2006 | 450 | 0.010 |
Why?
| | Cost Savings | 1 | 2003 | 86 | 0.010 |
Why?
| | Hospitals, University | 1 | 2003 | 176 | 0.010 |
Why?
| | Ultrasonography | 1 | 2006 | 795 | 0.010 |
Why?
| | Aspartate Aminotransferases | 1 | 2002 | 86 | 0.010 |
Why?
| | Alanine Transaminase | 1 | 2002 | 151 | 0.010 |
Why?
| | Child | 2 | 2016 | 22979 | 0.010 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2007 | 1166 | 0.010 |
Why?
| | Incidence | 1 | 2007 | 2954 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 2003 | 1550 | 0.010 |
Why?
| | Young Adult | 1 | 2016 | 14437 | 0.010 |
Why?
| | Liver Failure, Acute | 1 | 1998 | 70 | 0.010 |
Why?
| | Anastomosis, Surgical | 1 | 1998 | 167 | 0.010 |
Why?
| | Risk Assessment | 1 | 2008 | 3784 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2003 | 2133 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2002 | 2030 | 0.010 |
Why?
| | Age Factors | 1 | 2004 | 3372 | 0.010 |
Why?
| | Prevalence | 1 | 2003 | 2889 | 0.010 |
Why?
| | Models, Biological | 1 | 2003 | 1772 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2003 | 2973 | 0.010 |
Why?
| | Diabetes Mellitus | 1 | 2003 | 1107 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2006 | 3980 | 0.010 |
Why?
| | Child, Preschool | 1 | 2004 | 12016 | 0.000 |
Why?
|
|
Bak's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|